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Letters to the Editor 339In conclusion, pituitary TB presenting as pituitary apo-
plexy is very rare. This is only the second case reported in the
literature. A high index of clinical suspicion of pituitary TB is
warranted in endemic areas, even when the patient presents
with apoplexy-like symptoms.References
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infection in neutropenic patients successfully
treated with a combination of polymyxin B and
rifampin
Gram-negative bacillary infection remains a threat to
patients who become neutropenic after treatment for a
hematologic malignancy or stem cell transplantation, espe-
cially when the organism is resistant to multiple antibiotics.
Between May and December 2003, we saw four cases of
infection due to multidrug-resistant Pseudomonas aerugi-
nosa (MRPA) susceptible in vitro only to polymyxin B. This
drug acts synergistically in vitro with rifampin against multi-
drug-resistant Gram-negative bacilli, including Pseudomo-
nas aeruginosa.1,2 In a previous study, eight out of 12
patients who were infected by multidrug-resistant Serratia
marcescens were cured by this antibiotic combination.3
We therefore decided to try this treatment for two cases
of MRPA.
Patient A developed phlebitis and cellulitis accompanied
by high fever during the recovery phase of neutropenia, and
MRPA bacteremia was detected (Table 1). Treatment with
polymyxin B (1.0 mg/kg IV q12h) and rifampin (10 mg/kg IV
q12h) was commenced. Within a few hours she was admitted
to the ICU due to septic shock and respiratory failure resem-
bling acute respiratory distress syndrome, which necessi-
tated mechanical ventilation. Blood culture yielded MRPA24 hours after starting therapy but was sterile thereafter.
The phlebitis resolved, and she was weaned off vasopressors
andmechanical ventilation 12 and 14 days later, respectively.
This antibiotic combination was administered for 19 days and
was well tolerated.
Patient B had extensive cellulitis of the scalp with high
fever while being severely neutropenic. A specimen of pus
yielded MRPA on day 10. Polymyxin B (1.0 mg/kg IV q12h)
and rifampin (10 mg/kg IV q12h) were prescribed. The high
fever and scalp infection resolved. Granulocytes recovered
on day 17 of granulocyte colony-stimulating factor (G-CSF)
therapy. The antibiotic combination was administered for
21 days.
Treatment was well tolerated and toxicity was reduced by
employing saline hyperhydration (3 L/m2) in both cases, even
though its protective effect has not been proven. Previous
studies of critically ill patients have also shown a good
tolerance for polymyxin B.4,5 In both cases there was a
transient elevation of bilirubin up to 6 mg/dL during rifampin
administration that was reversed after the end of the treat-
ment.
The duration of polymyxin B—rifampin combination ther-
apy in this setting should be based on hematological recovery,
clinical response, and microbiological results.
These results suggest that the combination of polymyxin
B—rifampin is worth exploring further for treating neutro-
penic patients who develop infections due to multiply-resis-
tant P. aeruginosa.
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